Ardent Health Q2 hit by lower surgeries and admissions; cuts forecast
ARDT•Outlook
The company reaffirmed 2026 revenue guidance of $6.4 bln to $6.7 bln.
Ardent Health maintained its 2026 adjusted EBITDA forecast of $485 mln to $535 mln.
The company lowered 2026 net income and EPS guidance amid a lower volume outlook.
It said incremental benefit from the IMPACT program is expected to generate at least $70 mln savings in 2026, up from $55 mln previously.
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $1.62 bln | $1.59 bln (10 Analysts) |
| Q2 EPS | $0.12 | ||
| Q2 Net Income | $34.69 mln | ||
| Q2 Adjusted EBITDA | Beat | $115 mln | $110.24 mln (11 Analysts) |
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell".
The average consensus recommendation for the healthcare facilities & services peer group is "buy".
Wall Street's median 12-month price target for Ardent Health Inc is $12.00, about 11.6% above its August 3 closing price of $10.75.
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago.
